SCHEMBL3489635

SCHEMBL3489635

Nc1cc(Cl)cc(Cl)c1S(=O)(=O)NCc1ccc(Br)cc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.43
ALDH1A1 P00352 2/20 0.43
CA9 Q16790 2/20 0.41
CA12 O43570 1/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
MAPT P10636 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
NR3C1 P04150 4/20 0.39
NR3C2 P08235 4/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
PGR P06401 1/20 0.39
CYP3A4 P08684 1/20 0.38
LMNA P02545 1/20 0.38
SLC12A2 P55011 1/20 0.38
SLC12A5 Q9H2X9 1/20 0.38
PKM P14618 1/20 0.38
THRB P10828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3489075 0.90 ALDH1A1 (0.52) CYP19A1ALDH1A1CA9KMT2AMEN1
SCHEMBL3489110 0.88 ALDH1A1 (0.44) CYP19A1ALDH1A1CA9CA12KMT2A
SCHEMBL3488618 0.86 NSD2 (0.50) CYP19A1ALDH1A1CA9KMT2AMEN1
SCHEMBL3488631 0.86 KMT2A (0.52) CYP19A1ALDH1A1CA9CA12KMT2A
SCHEMBL3491178 0.86 LMNA (0.52) CYP19A1ALDH1A1CA9CA12KMT2A
SCHEMBL3489981 0.86 CYP19A1 (0.47) CYP19A1KMT2AMEN1MAPTNR3C1
SCHEMBL9275311 0.84 TP53 (0.41) CYP19A1ALDH1A1CA9KMT2AMEN1
SCHEMBL3491921 0.84 SMN1; SMN2 (0.53) ALDH1A1KMT2ALMNA
SCHEMBL3490641 0.83 LMNA (0.52) CYP19A1ALDH1A1MAPTLMNA
SCHEMBL9218252 0.83 NSD2 (0.52) CYP19A1ALDH1A1CA9KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME OPRD1, HTR6, HTR1D CYP19A1 1375/4885ALDH1A1 2748/4885CA9 4884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.